Olea europaea (OE) and Lippia citriodora (LC) are two botanical matrices well-known for their similar bioactive properties. Although they both share common families of phenolic compounds, their specific chemical compositions differ significantly. As the compounds from these plants undergo metabolic transformation in the body, particularly through phase I and phase II pathways, this study hypothesizes that common metabolite derivatives may arise, potentially contributing to their shared bioactive effects. Therefore, this study aims to identify common urinary metabolites derived from the intake of OE and LC leaf extracts. To achieve this, an acute double-blind dietary intervention was conducted with twenty-five volunteers, divided into three groups: OE (n=8), LC (n=8), and placebo (n=9). Urine samples were collected, before supplementation and afterwards at various intervals, and were analyzed using an untargeted metabolomic approach based on HPLC-ESI-QTOF-MS. Following data processing with MZmine and R packages, 18,823 molecular features were detected. Filtering steps and statistical analysis allowed the identification of exogenous metabolites derived from the extracts, revealing 580 and 424 significant features associated with the intake of OE and LC extracts, respectively. Notably, 129 molecular features were common to both matrices. Identification of significant molecular features was performed by comparing MS and MS/MS data with open-access metabolomics databases and existing literature. A total of 56 common features could be annotated, with phenolic acids derivatives (e.g., diferulic acid, homovanillic alcohol glucuronide etc.) as one of the most prominent families of bioavailable metabolites. In general, phase II metabolites, particularly sulfates and glucuronides, were the most predominant type of annotated metabolites. These findings underscore the potential of untargeted metabolomics in detecting bioavailable metabolites in urine after supplementation of bioactive extracts, enhancing the understanding of the bioactive mechanisms that could be useful for developing applications based on them, such as functional foods, nutraceuticals, or cosmeceuticals.